Article
Implementing liquid biopsy NGS in stage III/IV NSCLC: clinical utility assessment from a real-world Chinese cohort.
BMC cancer - 14 Nov 2025
Yang Xinxin, Gao Sihang, Ju Ran, Ji Xiaoyong, Deng Shuzhe, Guo Chenxu, Hou Yunjing, Pan Xiaoxi, Lin Lijiao, Qu Li, Wan Meixuan, Yang Shuo, Shan Guangyu, Meng Hongxue
Abstract excerpt
BACKGROUND: Cell-free circulating tumor DNA (ctDNA)-based next-generation sequencing (NGS) has demonstrated the potential to guide the personalized treatment of non-small cell lung cancer (NSCLC). Furthermore, clinical treatment-response data guided by ctDNA remain scarce. This study systematically evaluates an NGS platform’s detection accuracy and clinical utility in a large Chinese NSCLC cohort, establishing...
Topics
- Humans
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
- High-Throughput Nucleotide Sequencing
- Female
- Circulating Tumor DNA
- Male
- Neoplasm Staging
- Middle Aged
- Aged